OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 69,191 shares, a growth of 248.2% from the November 30th total of 19,869 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average trading volume of 200,019 shares, the short-interest ratio is presently 0.3 days. Based on an average trading volume of 200,019 shares, the short-interest ratio is presently 0.3 days. Approximately 0.3% of the company’s shares are sold short.

OKYO Pharma Trading Up 2.9%

Shares of NASDAQ OKYO traded up $0.06 during mid-day trading on Thursday, reaching $2.12. 21,415 shares of the company’s stock were exchanged, compared to its average volume of 142,311. OKYO Pharma has a twelve month low of $0.90 and a twelve month high of $3.35. The business has a fifty day simple moving average of $2.21 and a 200 day simple moving average of $2.37.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on OKYO shares. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of OKYO Pharma in a research report on Tuesday, September 23rd. B. Riley began coverage on OKYO Pharma in a report on Monday, December 8th. They set a “buy” rating and a $5.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OKYO Pharma in a research note on Wednesday, October 8th. Finally, Zacks Research upgraded shares of OKYO Pharma to a “hold” rating in a research report on Tuesday, September 16th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, OKYO Pharma currently has an average rating of “Hold” and a consensus price target of $6.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in OKYO Pharma stock. Wealth Enhancement Advisory Services LLC acquired a new position in shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,000 shares of the company’s stock, valued at approximately $28,000. 2.97% of the stock is owned by institutional investors.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.